NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Hyleukin-7TM, a T cell amplifier, in development for the treatment of Idiopathic CD4+ Lymphocytopenia (ICL).
April 16, 2019
· 3 min read